These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29653222)

  • 41. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
    Karaca M; Dutta R; Ozsoy Y; Mahato RI
    Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
    Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
    ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
    Mondal G; Almawash S; Chaudhary AK; Mahato RI
    Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells.
    Wu P; Wang X; Ma Y; Xu X; Liu W; Sheng Z; Chen M; Zhou R; Zhang K; Goodin S; Zheng X; Li D
    Bioorg Chem; 2020 Aug; 101():104022. PubMed ID: 32599367
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
    Kan S; Koido S; Okamoto M; Hayashi K; Ito M; Kamata Y; Komita H; Nagasaki E; Homma S
    BMC Cancer; 2015 Oct; 15():726. PubMed ID: 26475267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis.
    Ma J; Hui P; Meng W; Wang N; Xiang S
    Biochem Biophys Res Commun; 2017 Mar; 484(4):746-752. PubMed ID: 28153717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
    Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
    Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
    Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
    ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Androgen receptor blockade in experimental combination therapy of pancreatic cancer.
    Konduri S; Schwarz MA; Cafasso D; Schwarz RE
    J Surg Res; 2007 Oct; 142(2):378-86. PubMed ID: 17559882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
    Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
    Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
    Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
    Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
    Singh A; Xu J; Mattheolabakis G; Amiji M
    Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model.
    Paolino D; Licciardi M; Celia C; Giammona G; Fresta M; Cavallaro G
    Eur J Pharm Biopharm; 2012 Sep; 82(1):94-102. PubMed ID: 22705641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer.
    Park K
    J Control Release; 2016 Dec; 243():381. PubMed ID: 28024837
    [No Abstract]   [Full Text] [Related]  

  • 59. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
    Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
    J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Cathepsin B-Sensitive Gemcitabine Prodrug for Enhanced Pancreatic Cancer Therapy.
    Wang S; Cen D; Zhang C
    J Pharm Sci; 2024 Jul; 113(7):1927-1933. PubMed ID: 38555998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.